SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule.

Dickon Hayne; Nicole Swarbrick; Stephen McCombie; Andrew Moe; Cynthia Hawks; Pravin Viswambaram; Ciara Conduit; Elizabeth Chien Hern Liow; Lisa Spalding; Jarrad Bothe; Tom Ferguson; Andrew James Martin; Ian D. Davis; Andrew David Redfern

doi:10.1200/JCO.2022.40.6_suppl.483

SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule.

Dickon Hayne, Nicole Swarbrick, Stephen McCombie, Andrew Moe, Cynthia Hawks, Pravin Viswambaram, Ciara Conduit, Elizabeth Chien Hern Liow, Lisa Spalding, Jarrad Bothe, Tom Ferguson, Andrew James Martin, Ian D. Davis, Andrew David Redfern

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

1 Citation (Web of Science)

Original language	English
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	40
Issue number	6
DOIs	https://doi.org/10.1200/JCO.2022.40.6_suppl.483
Publication status	Published - 20 Feb 2022
Event	ASCO Genitourinary Cancers Symposium - Duration: 17 Feb 2022 → 19 Feb 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2022.40.6_suppl.483

Cite this

Hayne, D., Swarbrick, N., McCombie, S., Moe, A., Hawks, C., Viswambaram, P., Conduit, C., Liow, E. C. H., Spalding, L., Bothe, J., Ferguson, T., Martin, A. J., Davis, I. D., & Redfern, A. D. (2022). SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule. Journal of Clinical Oncology, 40(6). https://doi.org/10.1200/JCO.2022.40.6_suppl.483

@article{f1e143dd5e134c3784daa870b280816f,

title = "SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule.",

author = "Dickon Hayne and Nicole Swarbrick and Stephen McCombie and Andrew Moe and Cynthia Hawks and Pravin Viswambaram and Ciara Conduit and Liow, {Elizabeth Chien Hern} and Lisa Spalding and Jarrad Bothe and Tom Ferguson and Martin, {Andrew James} and Davis, {Ian D.} and Redfern, {Andrew David}",

year = "2022",

month = feb,

day = "20",

doi = "10.1200/JCO.2022.40.6_suppl.483",

language = "English",

volume = "40",

journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "6",

note = "ASCO Genitourinary Cancers Symposium ; Conference date: 17-02-2022 Through 19-02-2022",

}

Hayne, D , Swarbrick, N, McCombie, S, Moe, A, Hawks, C, Viswambaram, P, Conduit, C, Liow, ECH, Spalding, L, Bothe, J, Ferguson, T, Martin, AJ, Davis, ID & Redfern, AD 2022, 'SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule.', Journal of Clinical Oncology, vol. 40, no. 6. https://doi.org/10.1200/JCO.2022.40.6_suppl.483

TY - JOUR

T1 - SUB-urothelial durvalumab injection

T2 - ASCO Genitourinary Cancers Symposium

AU - Hayne, Dickon

AU - Swarbrick, Nicole

AU - McCombie, Stephen

AU - Moe, Andrew

AU - Hawks, Cynthia

AU - Viswambaram, Pravin

AU - Conduit, Ciara

AU - Liow, Elizabeth Chien Hern

AU - Spalding, Lisa

AU - Bothe, Jarrad

AU - Ferguson, Tom

AU - Martin, Andrew James

AU - Davis, Ian D.

AU - Redfern, Andrew David

PY - 2022/2/20

Y1 - 2022/2/20

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000771008900489

U2 - 10.1200/JCO.2022.40.6_suppl.483

DO - 10.1200/JCO.2022.40.6_suppl.483

M3 - Abstract/Meeting Abstract

VL - 40

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

SN - 0732-183X

IS - 6

Y2 - 17 February 2022 through 19 February 2022

ER -

SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule.

UN SDGs

Access to Document

Other files and links

Cite this